BC
GPCR icon

Birchview Capital’s Structure Therapeutics GPCR Stock Holding History

Birchview Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Sell
24,000
-76,000
-76% -$3.36M 0.6% 37
2026
Q1 		$4.82M Buy
100,000
+10,000
+11% +$684K 2.74% 8
2025
Q4 		$6.26M Buy
90,000
+12,000
+15% +$490K 3.66% 7
2025
Q3 		$2.18M Buy
78,000
+42,000
+117% +$837K 1.65% 14
2025
Q2 		$747K Buy
+36,000
New +$792K 0.74% 31

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Birchview Capital's GPCR Position: Q2 2026 in Review

Birchview Capital reduced its Structure Therapeutics (GPCR) stake by 76% in Q2 2026, selling an estimated $3.36M and leaving 24,000 shares worth $1.29M. The position accounts for 0.6% of the portfolio, ranked #37.

Birchview Capital first reported a position in GPCR in Q2 2025 and has held it in 5 quarters since. The position peaked at $6.26M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Birchview Capital held 24,000 shares of Structure Therapeutics worth $1.29M as of Q2 2026.
  • Birchview Capital sold 76,000 Structure Therapeutics shares in Q2 2026, an estimated $3.36M.
  • Structure Therapeutics made up 0.6% of Birchview Capital's portfolio in Q2 2026, its #37 holding.
  • Birchview Capital first reported a position in Structure Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Birchview Capital's Structure Therapeutics position peaked at $6.26M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.